Revive Therapeutics Ltd (CVE:RVV – Get Free Report) passed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of C$0.08 and traded as low as C$0.07. Revive Therapeutics shares last traded at C$0.08, with a volume of 212,852 shares.
Revive Therapeutics Stock Performance
The firm’s 50 day simple moving average is C$0.08 and its 200-day simple moving average is C$0.08. The company has a market capitalization of C$5.79 million and a price-to-earnings ratio of -3.64.
Revive Therapeutics Company Profile
Revive Therapeutics Ltd. develops and commercializes cannabinoid-based products in Canada. The company develops REV-002, a bucillamine that has completed Phase II-A clinical studies for the treatment of acute gout flares. Its product pipeline also includes REV-004, a bucillamine for the treatment of cystinurial. The company has a research and development supply and collaboration agreement with WeedMD Inc Revive Therapeutics Ltd. was incorporated in 2012 and is headquartered in Vaughan, Canada.
Further Reading
- Five stocks we like better than Revive Therapeutics
- Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
- Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock
- Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement
- Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For
Receive News & Ratings for Revive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
